Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Thursday.

According to Zacks, “Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “

Several other equities analysts have also commented on the stock. Leerink Swann reissued a “buy” rating and issued a $8.00 target price on shares of Dicerna Pharmaceuticals in a report on Tuesday, November 8th. Stifel Nicolaus reaffirmed a “buy” rating and set a $13.00 price target on shares of Dicerna Pharmaceuticals in a report on Wednesday, September 28th. Chardan Capital decreased their price target on shares of Dicerna Pharmaceuticals from $4.00 to $3.50 and set a “neutral” rating on the stock in a report on Monday, August 15th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Dicerna Pharmaceuticals in a report on Friday, August 5th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Dicerna Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $9.85.

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) opened at 3.70 on Thursday. The firm has a 50-day moving average of $4.10 and a 200 day moving average of $3.66. The company’s market cap is $76.79 million. Dicerna Pharmaceuticals has a 52 week low of $2.69 and a 52 week high of $15.93.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.17. The firm earned $162 million during the quarter. Equities analysts anticipate that Dicerna Pharmaceuticals will post ($2.95) earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the company. Oxford Asset Management increased its stake in Dicerna Pharmaceuticals by 109.3% in the second quarter. Oxford Asset Management now owns 286,413 shares of the biopharmaceutical company’s stock valued at $859,000 after buying an additional 149,560 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Dicerna Pharmaceuticals during the first quarter valued at approximately $343,000. Paloma Partners Management Co acquired a new stake in Dicerna Pharmaceuticals during the second quarter valued at approximately $183,000. A.R.T. Advisors LLC acquired a new stake in Dicerna Pharmaceuticals during the second quarter valued at approximately $170,000. Finally, FMR LLC increased its stake in Dicerna Pharmaceuticals by 0.4% in the second quarter. FMR LLC now owns 3,108,916 shares of the biopharmaceutical company’s stock valued at $9,327,000 after buying an additional 11,719 shares in the last quarter. Institutional investors and hedge funds own 62.37% of the company’s stock.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

5 Day Chart for NASDAQ:DRNA

Receive News & Stock Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.